In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with ...

Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding ...

Real-world benefit seen with addition of bevacizumab to first-line chemotherapy for patients with high‐risk prognostic factors.

Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.

Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

Ovarian cancer remains the leading cause of death among cancers affecting the female reproductive system, largely because ...

Turning pain into purpose is the aim of a Northland ovarian cancer patient, who hopes a song about her cancer fight will ...

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ovarian cancer has been launched. Treatment with a CAR-M cell therapy plus ...